We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App





EKF Diagnostics Highlights Assay Kit and POC Analyzer at AACC 2018

By LabMedica International staff writers
Posted on 01 Aug 2018
EKF Diagnostics (Cardiff, UK), a global in vitro diagnostics company, highlighted its new Stanbio Chemistry Glycated Albumin (GA) assay kit and its newly FDA cleared DiaSpect Tm hemoglobin point of care (POC) analyzer at the AACC 2018 Clinical Lab Expo held in Chicago, Illinois, from July 29 to August 2. More...
AACC is the world’s largest exposition for clinical laboratory products and services.

EKF Diagnostics manufactures POC and central laboratory technology, including tests for hemoglobin, HbA1c, glucose, lactate and a range of chemistry reagents. The company’s POC blood analyzers aid the diagnosis of anemia, diabetes and associated conditions, and its products are used by healthcare professionals in blood banks, GP surgeries, diabetes clinics, pharmacies, sports medicine, emergency rooms and laboratories.

At AACC 2018, EKF highlighted the Stanbio GA assay, which has FDA 510(k) clearance for sale in the US. The Stanbio Chemistry GA assay uses an enzymatic method with liquid reagents and does not require preparation. It can be used on compatible open channel clinical chemistry analyzers and expresses results as a ratio of GA to Albumin in mmol/mol from a small amount of blood serum.

EKF also demonstrated the use of its newly FDA 510(k) cleared and CLIA waived DiaSpect Tm hemoglobin analyzer at this year’s AACC. DiaSpect Tm analyzes whole blood from a sampling microcuvette designed to collect a blood sample from any angle without forming air bubbles, thus minimizing the need to repeat the testing procedure. DiaSpect Tm delivers lab quality hemoglobin results in about one second of the microcuvette being placed in the analyzer, making it the world’s fastest hemoglobin analyzer and ideal for efficient patient health checks and anemia screening at the POC. The hand-held and reagent free system is suitable and cleared for use in POC and Certificate of Waiver settings, including physician’s offices, clinics and other non-traditional laboratory locations.


New
Gold Member
Aspiration System
VACUSAFE
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The integrated polygenic risk score combines information from multiple genetic variants into a single test that provides a result for each of eight cardiovascular conditions (photo credit: Adobe Stock)

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.